Search
For optimal search results, please limit to 2 product keywords
If you are searching for information related to a product:
- For optimal results, please enter at least 2 search terms in addition to product name
- Example: [product name] [search term] [search term]
- Example: Product + clinical trials
- For an exact match, please include search terms in double quotations. For example: "Elevatum"
Modality: T cell-engaging bispecific antibody
Disease State: Previously untreated large B-cell lymphoma (LBCL), Relapsed or refractory mantle cell lymphoma (MCL)
Summary
Glofitamab is a bispecific antibody that binds to CD20 expressed on the surface of B cells and to the CD3 receptor expressed on the surface of T cells. Glofitamab causes T-cell activation and proliferation, secretion of cytokines, and the lysis of CD20-expressing B cells.1
Clinical Trials
| Large B-cell lymphoma (LBCL), Mantle cell lymphoma (MCL) | |||
|---|---|---|---|
| Phase | Enrollment Status | Title | |
| Phase III | Recruiting | A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Pola-R-CHP Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | View Details |
| Phase III | Recruiting | A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma | View Details |
Pola-R-CHP=polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone
Proposed Mechanism of Action
Glofitamab is a bispecific antibody that binds to CD20 expressed on the surface of B cells and to the CD3 receptor expressed on the surface of T cells. Glofitamab causes T-cell activation and proliferation, secretion of cytokines, and the lysis of CD20-expressing B cells.1
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT